Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus: The ADVANCE Trial

@article{Ohkuma2019AcuteII,
  title={Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus: The ADVANCE Trial},
  author={Toshiaki Ohkuma and Min Jun and Anthony Rodgers and Mark Emmanuel Cooper and Paul P. Glasziou and Pavel Hamet and Stephen B Harrap and Giuseppe Mancia and Michel Marre and Bruce Neal and Vlado Perkovic and Neil R. Poulter and Bryan L. Williams and Sophia Zoungas and John Chalmers and Mark Woodward},
  journal={Hypertension},
  year={2019},
  volume={73},
  pages={84–91}
}
Discontinuation of angiotensin-converting enzyme (ACE) inhibitor is recommended if patients experience ≥30% acute increase in serum creatinine after starting this therapy. However, the long-term effects of its continuation or discontinuation on major clinical outcomes after increases in serum creatinine are unclear. In the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation), 11 140 diabetes mellitus patients were randomly… Expand
Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes.
TLDR
Among real-world monitored adults, increases in creatinine (>10%) after initiation of RASi are associated with worse health outcomes, and these results suggest that patients with increases inCreatinine have higher subsequent risk of cardiovascular and kidney outcomes. Expand
Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction
TLDR
This review summarizes evidence from the literature regarding the use of RAS blockers in patients with advanced CKD and indicates that the fear of hyperkalemia or acute renal decline is another factor due to which RAS blocking drugs are usually underprescribed and are easily discontinued. Expand
Creatinine increase following initiation of antihypertensives is associated with cardiovascular risk: a nationwide cohort study.
TLDR
In primary care, patients initiating first-line antihypertensive treatment, an increase in plasma creatinine above 30% was associated with increased absolute 6-month risk of cardiovascular event. Expand
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.
TLDR
In people with type 2 diabetes and CKD, use of canagliflozin results in early, sustained reductions in albuminuria, which were independently associated with long-term kidney and cardiovascular outcomes. Expand
Renin-Angiotensin System Blockade in Advanced Kidney Disease: Stop or Continue?
TLDR
The risks for hyperkalemia and GFR decline have generated concerns and questions regarding maintaining RAS blocker therapy in patients with advanced CKD, and the answers to these questions are uncertain. Expand
Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial
TLDR
Data indicate that eGFR variability predict changes in the risk of major clinical outcomes in T2D, with evidence of a positive linear trend. Expand
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
TLDR
Following the initial drop in eGFR, multivariable adjusted long-term eG FR trajectories, as well as overall and kidney safety profiles, in those treated with canagliflozin were similar across eGfr decline categories, and safety outcomes were similar among subgroups of acute e GFR drop. Expand
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
TLDR
This study supports the utility of eGFR slope in type 2 diabetes as a surrogate endpoint for renal outcomes, as well as a prognostic factor for identifying individuals at high risk of cardiovascular disease and all-cause mortality. Expand
The challenge of early glomerular filtration rate decline in response to antihypertensive treatment and chronic kidney disease outcomes.
  • Lorenzo Signorini, G. Zaza, G. Gambaro
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2020
TLDR
The present review discusses the results of studies on the clinical significance of early GFR decline in response to treatment with angiotensin-converting enzyme inhibitor/angiotens in receptor blocker, or to different BP targets, in terms of renal and CV outcomes, and how this tips the balance towards continuing or discontinuing antihypertensive therapy. Expand
eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined
TLDR
It is not surprising that the major SGLT2i outcome trials have reported an early decline in eGFR shortly after initiating these drugs compared with placebo controls, but the aim is to put this observation into context, while providing clinicians with a practical approach to managing this scenario. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 23 REFERENCES
Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study
TLDR
Increases in creatinine after the start of angiotensin converting enzyme inhibitor/angiotens in receptor blocker treatment were associated with adverse cardiorenal outcomes in a graduated relation, even below the guideline recommended threshold of a 30% increase for stopping treatment. Expand
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
TLDR
Both increases and decreases in GFR on initiation of renin-angiotensin system blockade are common, and may be weakly associated with increased risk of cardiovascular and renal outcomes, but changes do not predict increased benefit from therapy. Expand
Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?
TLDR
A strong association exists between acute increases in serum creatinine of up to 30% that stabilize within the first 2 months of ACEI therapy and long-term preservation of renal function and withdrawal of an ACEI in patients with preexisting renal insufficiency is recommended. Expand
Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Cardiac Dysfunction
TLDR
Early WRF in the setting ofACE-I initiation appears to represent a benign event that is not associated with a loss of benefit from continued ACE-I therapy, and these data support the notion that the mechanism underlying WRF is important in determining its prognostic significance. Expand
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
TLDR
Routine administration of a fixed combination of perindopril and indapamide to patients with type 2 diabetes was well tolerated and reduced the risks of major vascular events, including death, which suggest that over 5 years, one death due to any cause would be averted. Expand
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.
TLDR
The greater the acute fall in glomerular filtration rate, during losartan treatment, the slower the rate of long-term eGFR decline, and interpretation of trial results relying on slope-based GFR outcomes should separate the initial drug-induced GFR change from the subsequent long- term effect on GFR. Expand
Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction: Insights From the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
TLDR
In patients with heart failure after acute myocardial infarction and receiving standard medical care, an early decline in eGFR is not uncommon and is associated with poor long-term outcome, and eplerenone induced a moderately more frequent early decline, which did not affect its clinical benefit on cardiovascular outcomes. Expand
Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction.
TLDR
Monitoring serum creatinine in patients during the first few weeks after MI may help to identify those who are at highest risk and guide effective long-term therapeutic choices. Expand
Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).
TLDR
The absolute benefit of spironolactone was greatest in patients with reduced eGFR, and the risk of hyperkalemia and renal failure was higher in those with worse baseline renal function and those with WRF, particularly in the spironOLactone arm, but the substantial net benefit ofSpironolACTone therapy remained. Expand
A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function.
TLDR
An initial fall in GFR after starting antihypertensive treatment in patients with a mild to moderate renal function impairment is reversible even after years of treatment, suggesting that this therapy-induced fall is of hemodynamic and not of structural origin. Expand
...
1
2
3
...